Ironwood Pharmaceuticals, Inc. (IRWD) Given Average Rating of “Hold” by Brokerages
Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) have been given a consensus rating of “Hold” by the eleven ratings firms that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $18.29.
IRWD has been the subject of several recent research reports. Cowen Inc set a $20.00 price objective on Ironwood Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 21st. Mizuho reissued a “buy” rating and set a $23.00 target price (up previously from $22.00) on shares of Ironwood Pharmaceuticals in a research report on Wednesday, August 2nd. ValuEngine raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, BidaskClub raised shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th.
Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at $15.64 on Friday. Ironwood Pharmaceuticals has a 52 week low of $13.43 and a 52 week high of $19.94. The company has a current ratio of 4.87, a quick ratio of 4.86 and a debt-to-equity ratio of -22.31.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.07. Ironwood Pharmaceuticals had a negative return on equity of 645.22% and a negative net margin of 48.89%. The company had revenue of $86.80 million during the quarter, compared to the consensus estimate of $73.59 million. During the same quarter in the prior year, the firm posted ($0.18) earnings per share. The firm’s revenue was up 31.3% compared to the same quarter last year. analysts anticipate that Ironwood Pharmaceuticals will post -1.12 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in IRWD. Gerber Kawasaki Wealth & Investment Management acquired a new stake in Ironwood Pharmaceuticals during the 3rd quarter valued at approximately $170,000. Teacher Retirement System of Texas acquired a new stake in shares of Ironwood Pharmaceuticals during the 2nd quarter worth approximately $192,000. Strs Ohio grew its position in shares of Ironwood Pharmaceuticals by 63.1% during the 2nd quarter. Strs Ohio now owns 10,600 shares of the biotechnology company’s stock worth $200,000 after buying an additional 4,100 shares during the period. Ameritas Investment Partners Inc. grew its position in shares of Ironwood Pharmaceuticals by 5.8% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock worth $223,000 after buying an additional 648 shares during the period. Finally, KCG Holdings Inc. grew its position in shares of Ironwood Pharmaceuticals by 20.5% during the 1st quarter. KCG Holdings Inc. now owns 14,270 shares of the biotechnology company’s stock worth $243,000 after buying an additional 2,428 shares during the period.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.
Receive News & Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.